Why the study?
Does high dose methotrexate lead to the excretion of 7-hydroxymethotrexate in human subjects and rhesus monkeys compared to conventional doses?
Does high dose methotrexate lead to the excretion of 7-hydroxymethotrexate in human subjects and rhesus monkeys compared to conventional doses?
High-dose methotrexate therapy leads to dose-dependent in vivo conversion to 7-hydroxymethotrexate in primates.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to metabolite formation in high-dose methotrexate; leaves open its clinical relevance and needs prospective validation.
Human subjects and rhesus monkeys receiving the antitumor agent methotrexate at the high dose levels recently introduced into clinical use (greater than 50 mg/kg) excrete significant amounts of the metabolite 7-hydroxymethotrexate. The metabolite is not detected in these species after methotrexate therapy at conventional dose levels. The evidence indicates that in primates, the in vivo conversion of methotrexate to 7-hydroxymethotrexate is a dose-dependent phenomenon, with the enzyme system(s) catalyzing the reaction having a low affinity for the drug.
No takes yet. Share an insight, caveat, or question.
Jacobs et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: